Prediction of relapse and survival in breast cancer patients by pS2 protein status.
about
Solution structure of a trefoil-motif-containing cell growth factor, porcine spasmolytic proteinTFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissuesTrefoil peptidesHITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancerDeficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice.An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patientspS2 is an independent factor of good prognosis in primary breast cancer.PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.pS2 and response to adjuvant hormone therapy in primary breast cancer.Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptorspNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.Expression of the pNR-2/pS2 protein in diverse human epithelial tumours.Pathological and biological features of mammographically detected invasive breast carcinomasRelationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.The mouse one P-domain (pS2) and two P-domain (mSP) genes exhibit distinct patterns of expression.Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy.PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancerTime at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.Activity of a Py-Im polyamide targeted to the estrogen response element.RETRACTED: Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.Oestrogen and progesterone receptor expression in mammary fibromatosis.Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancerGene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis.E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinomaBiological indices in the assessment of breast cancer.Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers.Production and comparison of mature single-domain 'trefoil' peptides pNR-2/pS2 Cys58 and pNR-2/pS2 Ser58.High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer.
P2860
Q27731246-150AE5ED-2E7D-40BD-9717-26F03CF60CF8Q27853155-6C3A3B3F-3CA3-4B87-874C-09D584D99129Q33400947-6B2C46D2-E78A-4B00-9459-76D0F319DF25Q33633535-68E4BECB-2F81-472A-B71E-CDB354E32AC1Q33970563-FBE188D7-B9C0-4609-8EDD-4E18F2C45689Q35120439-C32074AC-2D00-4266-BBEE-FF17B4DD47FBQ35927942-CD9C008A-EA22-44F6-9606-7E581DC0ED0FQ35976164-9BC30595-9CB3-4CA2-8688-8A3F4E50B473Q35977131-EBB8C3D9-865E-4745-ABC1-BEA97BB8D5DEQ35977596-DB421D85-CEAD-4DBB-8F76-5218A98115D5Q35978394-80F6BE10-2617-45DB-988C-3369DCFED252Q35984246-E6F95D09-7A8B-4667-B46A-5D330C7E12A6Q35993870-40186C89-51D0-4DD6-89F4-04C4BCD11D35Q36079849-4B475510-E444-44F4-8FFA-351CE4D9DDB6Q36080684-44F476D3-5379-4C42-9D8A-6B9E84077AA6Q36232620-F2733177-CB8E-422F-9178-C57F8C8A1417Q36292107-51933FEC-1C13-4628-8F9F-B2E813652D6DQ36295086-69F5D9AB-404A-4381-97D8-50D251B0B59CQ36618820-F5412E08-3E6B-4442-8B75-F56E2B2DECC0Q36836841-03280A60-AEA3-403E-8FAE-F6D31B5F1E66Q37129445-55A72C76-2BFA-4361-9C14-EEF6235B3522Q37233847-8F0ED518-3DD8-4ACD-8B62-14F75BCDEE6EQ37248242-DC282198-A78B-4328-94C4-E7EE4D5BE827Q37327550-E85CAA65-EB65-4F8C-87DA-F6980EEFE2C9Q40027797-4DAA777E-F187-46B1-A065-FAE81841FE7BQ40848953-0D51AF48-0071-4338-B3B4-768B830DAB5EQ42005592-362EA4FC-090B-4D38-B65F-B50D5E347D00Q42826311-A5A96156-4395-4FE2-A149-B59DAD8E1AB1Q55515027-A01DB2C4-7B02-4241-89C5-9EDDA1C5322F
P2860
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
description
1990 nî lūn-bûn
@nan
1990 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@ast
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@en
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@nl
type
label
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@ast
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@en
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@nl
prefLabel
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@ast
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@en
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@nl
P2093
P1433
P1476
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
@en
P2093
J A Foekens
W L van Putten
P304
P407
P577
1990-07-01T00:00:00Z